Navigation Links
Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
Date:12/14/2011

the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.

 Champions Oncology, Inc.Reconciliation of GAAP to Non-GAAP Net Loss(Amounts in thousands except for loss per share amounts) 

Three Months Ended

October 31,

 

Six Months Ended

October 31, 

2011

2010

 

2011

2010Net loss attributable to Champions – GAAP

($2,349)

($54)

 

($4,386)

($645)Less:

Stock-based compensation

 

855

 

197

 

 

1,867

 

367Net income (loss) attributable to Champions-non-GAAP:

($1,494)

$143

 

($2,159)

($278) 

Net income (loss) per common share attributable to Champions – non GAAP:

 

 

 

 

 Basic and diluted

($0.03)

$0.00

 

($0.05)

($0.01) 

CONTACT:
Susan Foreman
Champions Oncology, Inc.
+1-410-369-0365


'/>"/>
SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Champions CFO Resigns
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PORTLAND, Oregon , August 28, 2014 /PRNewswire/ ... Market Research titled, "DNA diagnostics Market (products, applications, ... Analysis, Trends, Opportunities, Growth and Forecast, 2013 - ... would reach $19 billion by 2020 registering a ... potential to provide accurate diagnosis and cost effectiveness ...
(Date:8/28/2014)...  In recognition of the increased risks that ... flu, pneumonia, shingles and other illnesses, CVS/pharmacy ® ... to be Senior Vaccination Month. Because people,s immune ... that adults ages 65 years and older stay ... and MinuteClinic nurse practitioners and physician assistants will ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... June 08, 2007 /PRNewswire-FirstCall/ --,Lexicon Pharmaceuticals, Inc. today ... research project with scientists at Fox,Chase Cancer Center ... Lexicon researchers have discovered a novel and,surprising role ... T lymphocytes. These findings have been published in,the ...
... - NuPathe Inc., a,privately held specialty pharmaceutical ... Phase I study of NP101,SmartRelief, a novel ... NP101 combines NuPathe's SmartRelief(TM) proprietary,iontophoretic transdermal technology ... acute migraine in the United,States. Sumatriptan is ...
Cached Medicine Technology:Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 2Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 3NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 2NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 3
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet meal ... Vegetarian meal plan. Originating from The Fresh Diet’s commitment ... is designed to satisfy customers seeking a convenient, worry-free ... Responding to the growing demand by customers for non-meat ... (Forbes) with 14% of Americans identifying vegetarian meals as ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- The main strain ... Middle East and North Africa originated in sub-Saharan ... so-called community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) ... not recently been hospitalized. These infections typically affect ... contact or through touching contaminated objects such as ...
(Date:8/29/2014)... Parker Waichman LLP, a national law ... rights of victims who have been injured by medications ... new regulations for all hydrocodone combination products. According to ... dated August 21, 2014, the DEA will be regulating ... law. , The long-awaited announcement comes after a ...
(Date:8/29/2014)... 2014 TayganPoint Consulting Group, a leading ... second time, Inc. Magazine has named the company one ... Based on solid revenue growth of over 166% over ... on the list. TayganPoint’s repeat success in this ... past few years, is a demonstration of its strong ...
(Date:8/29/2014)... 2014 Gwyneth Paltrow, Beyonce and Angelina Jolie ... have inspired dieters all over the United States, to find ... to help them quickly shed excess fat. And, recent inspiration ... that substitutes all gluten products, eggs and meats for ingredients ... associated with following this type of diet, one must be ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Diet Doc Announces Diet Plans that Deliver Fast Weight Loss Results at a Fraction of the Cost of Celebrity Diets 2Health News:Diet Doc Announces Diet Plans that Deliver Fast Weight Loss Results at a Fraction of the Cost of Celebrity Diets 3
... Migraine is a neurovascular disease that affects about ... and beverages (chocolate, wine, citrus, etc) considered as ... and phenolic compounds. Avoiding those triggers may ... patients. However, only a small percentage ...
... reduce the use of mechanical ventilation with premature infants ... can profoundly affect those children,s outcomes while reducing the ... at Children,s Hospital Boston. The team, led ... Medicine at Children,s Hospital Boston and the Neonatal Intensive ...
... The American Association for Cancer Research is pleased to ... their families and caregivers won first place in ... of Colon and Rectal Surgeons. Separately, it received three ... the Society of Professional Journalists. "We are ...
... Daytime sleepiness may affect inhibitory control in the ... research abstract that will be presented Monday, June ... 25th Anniversary Meeting of the Associated Professional Sleep ... daytime sleepiness was associated with decreased activation in ...
... insomnia may be able to find relief by wearing a ... abstract that will be presented Monday, June 13, in Minneapolis, ... Associated Professional Sleep Societies LLC (APSS). According to the ... occurs while falling asleep and is associated with restorative sleep. ...
... Multiple Sclerosis sufferers emotional support through group therapy sessions ... NHS almost 500 per patient, a study at The ... planning a larger multi-centre study into the issue to ... MS services currently provided by the NHS. The ...
Cached Medicine News:Health News:The association of alcohol drinking with migraine headache 2Health News:Guidelines for ventilator use help premature infants breathe easier 2Health News:AACR's CR magazine honored with 4 prestigious journalism awards 2Health News:Sleepiness may impair the brain's inhibitory control when viewing high-calorie foods 2Health News:Cooling the brain during sleep may be a natural and effective treatment for insomnia 2Health News:Cooling the brain during sleep may be a natural and effective treatment for insomnia 3Health News:Group therapy helps MS sufferers cope with depression, study finds 2Health News:Group therapy helps MS sufferers cope with depression, study finds 3
... is the least expensive of the series. It has ... central area of the cornea. The model comes with ... a picture of a patients corneal endothelium, you simply ... on the chin rest. The left side of the ...
... The JSZ Orthokeratology (oprifocon ... gas permeable contact lenses used ... temporarily corrects nearsightedness (myopia). The ... and removes them in the ...
... contact lenses used for corneal refractive therapy, ... The patient wears the lenses overnight while ... the day, nearsightedness is corrected or greatly ... contact lenses apply slight pressure to the ...
... Looking for a way to help your ... cardiovascular disease? Based on the outcomes ... Counterpulsation (ECP) has improved the quality of ... perform normal activities of daily living. , ...
Medicine Products: